Literature DB >> 15888646

The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression.

Jun Ming Wang1, Patrick B Johnston, Bret Gene Ball, Roberta Diaz Brinton.   

Abstract

Our previous research demonstrated that the neuroactive progesterone metabolite allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one) rapidly induced hippocampal neuron neurite regression (Brinton, 1994). We hypothesized that allopregnanolone-induced neurite regression was a prelude to mitogenesis initiated by a rise in intracellular calcium. Supporting this hypothesis, the current data demonstrate that allopregnanolone, in a dose-dependent manner, induces a significant increase in proliferation of neuroprogenitor cells (NPCs) derived from the rat hippocampus and human neural stem cells (hNSCs) derived from the cerebral cortex. Proliferation was determined by incorporation of bromodeoxyuridine and [3H]thymidine, fluorescence-activated cell sorter analysis of murine leukemia virus-green fluorescent protein-labeled mitotic NPCs, and total cell number counting. Allopregnanolone-induced proliferation was isomer and steroid specific, in that the stereoisomer 3beta-hydroxy-5beta-pregnan-20-one and related steroids did not increase [3H]thymidine uptake. Immunofluorescent analyses for the NPC markers nestin and Tuj1 indicated that newly formed cells were of neuronal lineage. Furthermore, microarray analysis of cell-cycle genes and real-time reverse transcription-PCR and Western blot validation revealed that allopregnanolone increased the expression of genes that promote mitosis and inhibited the expression of genes that repress cell proliferation. Allopregnanolone-induced proliferation was antagonized by the voltage-gated L-type calcium channel (VGLCC) blocker nifedipine, consistent with the finding that allopregnanolone induces a rapid increase in intracellular calcium in hippocampal neurons via a GABA type A receptor-activated VGLCC (Son et al., 2002). These data demonstrate that allopregnanolone significantly increased rat NPC and hNSC proliferation with concomitant regulation in mitotic cell-cycle genes via a VGLCC mechanism. The therapeutic potential of allopregnanolone as a neurogenic molecule is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888646      PMCID: PMC6724768          DOI: 10.1523/JNEUROSCI.4520-04.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  85 in total

1.  Calcium dynamics of neocortical ventricular zone cells.

Authors:  D F Owens; A C Flint; R S Dammerman; A R Kriegstein
Journal:  Dev Neurosci       Date:  2000       Impact factor: 2.984

Review 2.  Proteolysis and the cell cycle: with this RING I do thee destroy.

Authors:  M Tyers; P Jorgensen
Journal:  Curr Opin Genet Dev       Date:  2000-02       Impact factor: 5.578

3.  Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice.

Authors:  M Yamaguchi; H Saito; M Suzuki; K Mori
Journal:  Neuroreport       Date:  2000-06-26       Impact factor: 1.837

4.  In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus.

Authors:  N S Roy; S Wang; L Jiang; J Kang; A Benraiss; C Harrison-Restelli; R A Fraser; W T Couldwell; A Kawaguchi; H Okano; M Nedergaard; S A Goldman
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

5.  Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia.

Authors:  F Bernardi; A Lanzone; R M Cento; R S Spada; I Pezzani; A D Genazzani; S Luisi; M Luisi; F Petraglia; A R Genazzani
Journal:  Eur J Endocrinol       Date:  2000-05       Impact factor: 6.664

6.  Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients.

Authors:  S Luisi; F Petraglia; C Benedetto; R E Nappi; F Bernardi; M Fadalti; F M Reis; M Luisi; A R Genazzani
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

7.  Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain.

Authors:  I H Zwain; S S Yen
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

8.  Cell cycle kinetics and immunohistochemical characterization of dissociated fetal neocortical cultures: evidence that differentiated neurons have mitotic capacity.

Authors:  J S Jacobs; M W Miller
Journal:  Brain Res Dev Brain Res       Date:  2000-07-30

9.  In vivo evidences of early neurosteroid synthesis in the developing rat central nervous system and placenta.

Authors:  P E Pomata; A A Colman-Lerner; J L Barañao; M L Fiszman
Journal:  Brain Res Dev Brain Res       Date:  2000-03-15

Review 10.  Steroid metabolism and effects in central and peripheral glial cells.

Authors:  R C Melcangi; V Magnaghi; L Martini
Journal:  J Neurobiol       Date:  1999-09-15
View more
  100 in total

1.  Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease.

Authors:  Jun Ming Wang; Chanpreet Singh; Lifei Liu; Ronald W Irwin; Shuhua Chen; Eun Ji Chung; Richard F Thompson; Roberta Diaz Brinton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 2.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

Review 3.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  Ischemic insult to cerebellar Purkinje cells causes diminished GABAA receptor function and allopregnanolone neuroprotection is associated with GABAA receptor stabilization.

Authors:  Melissa H Kelley; Noriko Taguchi; Ardalan Ardeshiri; Masayuki Kuroiwa; Patricia D Hurn; Richard J Traystman; Paco S Herson
Journal:  J Neurochem       Date:  2008-09-18       Impact factor: 5.372

7.  Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury.

Authors:  Cindy K Barha; Tauheed Ishrat; Jonathan R Epp; Liisa A M Galea; Donald G Stein
Journal:  Exp Neurol       Date:  2011-06-13       Impact factor: 5.330

8.  Simultaneous quantification of GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in human and rat serum.

Authors:  Patrizia Porcu; Todd K O'Buckley; Sarah E Alward; Christine E Marx; Lawrence J Shampine; Susan S Girdler; A Leslie Morrow
Journal:  Steroids       Date:  2009-01-13       Impact factor: 2.668

9.  The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus.

Authors:  Smita Thakker-Varia; Jennifer Jernstedt Krol; Jacob Nettleton; Parizad M Bilimoria; Debra A Bangasser; Tracey J Shors; Ira B Black; Janet Alder
Journal:  J Neurosci       Date:  2007-11-07       Impact factor: 6.167

Review 10.  Neuroendocrine pathways underlying risk and resilience to PTSD in women.

Authors:  Meghna Ravi; Jennifer S Stevens; Vasiliki Michopoulos
Journal:  Front Neuroendocrinol       Date:  2019-09-19       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.